Brief: Inhibikase Therapeutics Announces FDA Lifts Full Clinical Hold On IkT-148009
08/03/2023 17:46
March 8 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES FDA HAS LIFTED THE FULL
CLINICAL HOLD ON IKT-148009 IN MULTIPLE SYSTEM ATROPHY
* INHIBIKASE THERAPEUTICS - ADVANCING MODEL STUDIES OF
IKT-148009
IN MSA
* INHIBIKASE THERAPEUTICS INC - PLANNED PHASE 2A '202'
CLINICAL
TRIAL WILL EVALUATE THERAPEUTIC BENEFIT OF IKT-148009 OVER 6
MONTHS
Source text for Eikon: ID:nPnbrwLmka
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share